fda tirzepatide says the weight-loss drug shortage is over Compounded Semaglutide & Tirzepatide 2025:

In the SUSTAIN program trials, gastrointestinal adverse events were the most common reason for discontinuation, with nausea, vomiting, diarrhea, and belching all linked mechanistically to this delayed transit

Obesity treatments using GLP-1 receptor agonists focus on weight management by promoting satiety, thereby reducing food intake and assisting in sustained weight loss

Berthold Pemp: declares no conflict of interest relevant to this study

Liraglutide: Well-characterized GI side effects (nausea, vomiting, diarrhea)

The ministrys announcement comes with the instruction that physicians must no longer prescribe Ozempic for off-label use for weight loss, a practice approved by the FDA in 2021

As is toxic for plants, humans, and the environment